Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Changes in Macular Thickness After Patterns Scan Laser

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: November 22, 2007
Last updated: November 23, 2007
Last verified: November 2007
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in TMD. The aim is to destroy a substantial portion of the peripheral retina in order to reduce the angiogenic stimulus (decrease the difference between oxygen demand and the administration). Their effectiveness is determined by the extent of destruction of the retina (2.4).

Condition Intervention Phase
Non Proliferative Diabetic Retinopathy.
Proliferative Diabetic Retinopathy.
Device: Panretinal photocoagulation with PASCAL system
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Retinal thickness after treatment [ Time Frame: 12 weeks ]

Estimated Enrollment: 8
Study Start Date: October 2007
Estimated Study Completion Date: February 2008
Intervention Details:
    Device: Panretinal photocoagulation with PASCAL system
    Use the PASCAL laser system to deliver a retina photocoagulation
    Other Name: Pattern Scan Laser system
  Show Detailed Description


Ages Eligible for Study:   25 Years to 95 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than 25 years, with a diagnosis of severe NPDR or PRD.
  • Good pupil mydriasis (minimum 5mm) With clear media
  • Patients without previous laser treatment or treatment with antiangiogenic drug.

Exclusion Criteria:

  • Patients who do not accept informed consent.
  • Patients with clinical macular Edema before treatment.
  • Significant corneal opacity.
  • Patients with other eye diseases that interfere with the studies required for the monitoring of patients.
  • History of refractive surgery, glaucoma or ocular hypertension, intraocular inflammation, choroiditis multifocal, retinal detachment, optic neuropathy (4).
  • Patients with tractional retinal detachment due to abundant fibrovascular tissue. Or important fibrovascular tissue that fold or detach the retina.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00563628

Asociaciòn para Evitar la Ceguera en Mèxico
Mexico, DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Raul Velez-Montoya, MD Ascoiaciòn para Evitar la Ceguera en Mexico
Principal Investigator: Hugo Quiroz-Mercado, MD Asociaciòn para Evitar la Ceguera
Principal Investigator: Virgilio Morales-Canton, MD Asociaciòn para Evitar la Ceguera
  More Information

Publications: Identifier: NCT00563628     History of Changes
Other Study ID Numbers: PASCAL001 
Study First Received: November 22, 2007
Last Updated: November 23, 2007
Health Authority: Mexico: Ministry of Health

Keywords provided by Asociación para Evitar la Ceguera en México:
Pattern Scan Laser.
Diabetic retinopathy treatment.
Laser treatment

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases processed this record on January 14, 2017